Duan, Qingling - Queen's University - Department of Biomedical and Molecular Sciences

个人简介

Academic Appointments 2012-2015 Instructor in Medicine, Harvard Medical School & Brigham and Women’s Hospital 2009-2012 Postdoctoral Fellowship, Harvard Medical School & Brigham and Women’s Hospital 2002-2009 Ph.D. in Human Genetics, McGill University 1999-2002 B.Sc. in Biology, McGill University Funding/Awards 2016-2017 William M. Spear Endowment Fund in Pulmonary Research (Co-Investigator) 2016-2020 Canadian Institutes of Health Research (Co-Investigator) 2016-2017 Canadian Foundation for Innovation 2016-2018 Queen's Research Leaders' Fund, Queen's University 2015-2016 University Hospitals Kingston Foundation (Co-Investigator) 2015-2020 Queen’s National Scholar, Queen’s University 2013-2015 Pathway to Independence (K99), National Heart, Lung and Blood Institute (NHLBI) 2009-2012 Postdoctoral Fellowship, Canadian Institutes of Health Research 2006-2008 Doctoral Research Award, Heart and Stroke Foundation of Canada 2006-2009 Doctoral Research Award, Fonds de Recherche en Santé du Québec (Declined) Genomics and Pharmacogenomics The primary objective of my research is to identify genomic factors that regulate drug response or susceptibility to multifactorial diseases (e.g. asthma, COPD, cardiovascular diseases and various cancers). My research focus stems from my graduate studies in Human Genetics at McGill University and my postdoctoral training with the respiratory genomics/pharmacogenomics group in the Channing Division of Network Medicine at Harvard Medical School. Specifically, I have used statistical and machine-learning methods to identify novel genomic factors correlated with variable esponse or adverse reactions to drugs commonly prescribed for cardiovascular or respiratory diseases. My current research integrates variable biomedical data (i.e. genomics, transcriptomics and epigenomics) for gene-based, network-based as well as gene-environment interaction analyses to identify novel genomic regulators of disease risk (e.g., asthma, COPD, diabetes) and other clinical outcomes (e.g. symptom severity, lung function). This work is in collaboration with clinicians and basic scientists across multiple disciplines at Queen’s, Kingston General Hospital, Hotel-Dieu Hospital, the Canadian Respiratory Research Network (CRRN), The Allergy, Genes and Environment Network (AllerGen), as well as other national and international centers.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Brehm JM, Ramratnam SK, Tse SM, Croteau-Chonka DC, Pino-Yanes M, Rosas-Salazar C, et al., Stress and Bronchodilator Response in Children with Asthma. Am J Respir Crit Care Med. 2015 Jul 1;192(1):47-56. doi:10.1164/rccm.201501-0037OC 2.Qiu W, Rogers AJ, Damask A, Raby BA, Klanderman BJ, Duan QL, et al., Pharmacogenomics: Novel Loci Identification via Treatment-Specific eQTL Analysis. Hum Mol Genet. 2014 Sep 15;23(18):5017-24. doi: 10.1093/hmg/ddu191. 3.Himes BE, Jiang X, Wagner P, Hu R, Klanderman BJ, Whitaker RM, et al., RNA-seq Transcriptome Profiling Identifies CRISPLD2 as a Novel Glucocorticoid Responsive Gene that Regulates Immune Response in Airway Smooth Muscle Cells. PLoS One. 2014 Jun 13;9(6):e99625. doi: 10.1371/journal.pone.0099625 4.Park HW, Dahlin A, Tse S, Duan QL, Schuemann B, Martinez FD, et al., Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014 Mar;133(3):664-9.e5. 5.Duan QL*, Lasky-Su J*, Himes BE, Qiu W, Litonjua AA, Damask A, et al., A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J. 2014 Feb;14(1):41-7. *Co-authors 6.Duan QL, Du R, Lasky-Su J, Klanderman B, Partch AB, Peters SP, et al., Association of transcription factor genes with bronchodilator response in asthmatics. Pharmacogenomics J. 2013 Apr;13(2):130-6. doi: 10.1038/tpj.2011.56. 7.Cilia La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A, et al., A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat. 2011 Nov;32(11):1326-31. doi: 10.1002/humu.21579. 8.Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Lange C, et al., Genome-wide Association Analysis of Asthma Steroid Treatment Response Identifies GLCCI1 as a Novel Pharmacogenetic Locus. N Engl J Med. 2011 Sep 29;365(13):1173-83. doi: 10.1056/NEJMoa0911353. 9.Grundberg E, Adoue V, Kwan T, Ge B, Duan QL, Lam KCL, et al., Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet. 2011 Jan 20;7(1):e1001279. doi: 10.1371/journal.pgen.1001279. 10.Duan QL, Gaume BR, Hawkins GA, Himes BE, Bleecker ER, Klanderman B, et al., Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med. 2011 Feb 15;183(4):449-54. doi: 10.1164/rccm.201005-0758OC. 11.Harada M, Hirota T, Jodo AI, Hitomi Y, Sakashita M, Tsunoda T, et al., TSLP Promoter Polymorphisms are Associated with Susceptibility to Bronchial Asthma. Am J Respir Cell Mol Biol. 2011 Jun;44(6):787-93. doi: 10.1165/rcmb.2009-0418OC.